Prevalence of Factor V Leiden in Accelerated Forms of Coronary Artery Disease

• References

• 1 Dahlbäck B. New Molecular Insights into the Genetics of Thrombophilia: Resistance to Activated Protein C Caused by Arg506 to Gin Mutation in Fac tor V as a Pathogenic Risk Factor for Venous Thrombosis. Thromb Haemost 1995; 74 (01) 139-148
• 2 Svensson PJ, Dahlbäck B. Resistance of Activated Protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522
• 3 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men. N Engl J Med 1995; 332: 912-917
• 4 Samani NJ, Lodwick D, Martin D, Kimber P. Resistance to Activated Protein C and Risk of Premature Myocardial Infarction. Lancet 1994; 344: 1709-1710
• 5 Holm J, Zӧller B, Svensson PJ, Bemtorp E, Erhardt L, Dahlbäck B. Myocar dial Infarction Associated with Homozygous Resistance to Activated Protein C. Lancet 1994; 344: 952-953
• 6 Marz W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in Coagulation Factor V Associated with Resistance to Activated Protein C in Patients with Coronary Artery Disease. Lancet 1995; 345: 526-527
• 7 Labarrere CA, Pitts D, Nelson DR, Faulk WP. Vascular Tissue Plasminogen Activator and the Development of Coronary Artery Disease in Heart-Trans- plant Recipients. N Engl J Med 1995; 333: 1111-1116
• 8 Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic Distribution of Factor V Leiden Among 4047 Men and Women: Implications for Screening and Prevention of Venous Thromboembolism. JAMA 1997; 277: 1305-1307